Amylin CEO on Diabetes & Diet Drugs

The FDA has approved Amylin's Byetta as a stand-alone diabetes drug. The company's CEO, Daniel Bradbury, discusses the approval and more with CNBC's Mike Huckman.

CNBC | November 2, 2009

Tags:. .huckman. .cnbc. .bradbury. .diabetes. .fda